Contact Informatie voor patiƫnten Enrolment new DCCG study Menu

TASCO-1

Acronym

TASCO-1

Name of the study

An open-label, randomised, phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated metastatic colorctal cancer who are non-eligible for intensive therapy

Researchers and contact information

National Coordinator

Prof.dr. C.J.A. Punt

Academic Medical Center, University of Amsterdam

E-mail: c.punt@amc.uva.nl

Summary study

First-line treatment of metastatic colorectal cancer in patients non-eligible for intensive therapy

Intervention

Experimental arm: Trifluridine/tipiracil (TAS-102, Lonsurf) + bevacizumab

Control arm: capecitabine + bevacizumab

Documents